Liver transplantation for hepatocellular carcinoma: Outcomes and treatment options for recurrence

Annals of Gastroenterology

Volumn 28, Issue 3, 2015, Pages 321-328

  Rahimi, Robert S ^a   Trotter, James F ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Deceased donor; Liver cancer; Living donor; mTOR; Sirolimus; Sorafenib

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SORAFENIB;

ARTICLE; ASTHENIA; CADAVER DONOR; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CAUSE OF DEATH; CHEMOEMBOLIZATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GRAFT SURVIVAL; HAND FOOT SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; META ANALYSIS (TOPIC); MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84931446158     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Organization. WH. Mortality Database. WHO StatisticalInformation System 2008
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma:epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557-2576
3. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellularcarcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-680
4. Ioannou GN, Perkins JD, Carithers RL, Jr. Liver transplantation forhepatocellular carcinoma: impact of the MELD allocation systemand predictors of survival. Gastroenterology 2008;134:1342-1351
5. Freeman RB, Jr., Wiesner RH, Harper A, et al. Th e new liverallocation system: moving toward evidence-based transplantationpolicy. Liver Transplant 2002;8:851-858
6. Washburn K. Model for end stage liver disease and hepatocellularcarcinoma: a moving target. Transplant Rev (Orlando) 2010;24:11-17
7. Freeman RB, Jr., Steffi ck DE, Guidinger MK, et al. Liver andintestine transplantation in the United States, 1997-2006. Am JTransplant 2008;8:958-976
8. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation forthe treatment of small hepatocellular carcinomas in patients withcirrhosis. N Engl J Med 1996;334:693-699
9. Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations forliver transplantation for hepatocellular carcinoma: an internationalconsensus conference report. Lancet Oncol 2012;13:11-22
10. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation forhepatocellular carcinoma: expansion of the tumor size limits doesnot adversely impact survival. Hepatology 2001;33:1394-1403
11. Yao FY, Xiao L, Bass NM, et al. Liver transplantation forhepatocellular carcinoma: validation of the UCSF-expanded criteriabased on preoperative imaging. Am J Transplant 2007;7:2587-2596
12. Berg CL, Steffi ck DE, Edwards EB, et al. Liver and intestinetransplantation in the United States 1998-2007. Am J Transplant2009;9:907-931
13. Onaca N, Davis GL, Goldstein RM, et al. Expanded criteria forliver transplantation in patients with hepatocellular carcinoma: areport from the International Registry of Hepatic Tumors in LiverTransplantation. Liver Transplant 2007;13:391-399
14. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival aft erliver transplantation in patients with hepatocellular carcinomabeyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43
15. Millonig G, Graziadei IW, Freund MC, et al. Response topreoperative chemoembolization correlates with outcome aft erliver transplantation in patients with hepatocellular carcinoma. Liver Transplant 2007;13:272-279
16. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequencyablation of small hepatocellular carcinoma in cirrhotic patientsawaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909
17. Maddala YK, Stadheim L, Andrews JC, et al. Drop-outrates of patients with hepatocellular cancer listed for livertransplantation: outcome with chemoembolization. LiverTransplant 2004;10:449-455
18. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of thepattern and predictors of dropout from the waiting list for livertransplantation in patients with hepatocellular carcinoma:implications for the current organ allocation policy. LiverTransplant 2003;9:684-692
19. Washburn K, Edwards E, Harper A, et al. Hepatocellular carcinomapatients are advantaged in the current liver transplant allocationsystem. Am J Transplant 2010;10:1643-1648
20. Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis ofliver transplantation for hepatocellular carcinoma: living versusdeceased donor transplantation. Hepatology 2011;53:1570-1579
21. Hwang S, Lee SG, Joh JW, et al. Liver transplantation for adultpatients with hepatocellular carcinoma in Korea: comparisonbetween cadaveric donor and living donor liver transplantations. Liver Transplant 2005;11:1265-1272
22. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinomarecurrence and death following living and deceased donor livertransplantation. Am J Transplant 2007;7:1601-1608
23. Lo CM, Fan ST, Liu CL, et al. Living donor versus deceaseddonor liver transplantation for early irresectable hepatocellularcarcinoma. Brit J Surg 2007;94:78-86
24. Vakili K, Pomposelli JJ, Cheah YL, et al. Living donor livertransplantation for hepatocellular carcinoma: Increased recurrencebut improved survival. Liver Transplant 2009;15:1861-1866
25. Di Sandro S, Slim AO, Giacomoni A, et al. Living donor livertransplantation for hepatocellular carcinoma: long-term resultscompared with deceased donor liver transplantation. TransplantProc 2009;41:1283-1285
26. Grant RC, Sandhu L, Dixon PR, et al. Living vs. deceased donorliver transplantation for hepatocellular carcinoma: a systematicreview and meta-analysis. Clin Transplant 2013;27:140-147
27. Liang W, Wu L, Ling X, et al. Living donor liver transplantationversus deceased donor liver transplantation for hepatocellularcarcinoma: a meta-analysis. Liver Transplant 2012;18:1226-1236
28. Kulik LM, Fisher RA, Rodrigo DR, et al. Outcomes of living anddeceased donor liver transplant recipients with hepatocellularcarcinoma: results of the A2ALL cohort. Am J Transplant 2012;12:2997-3007
29. Cescon M, Ravaioli M, Grazi GL, et al. Prognostic factors fortumor recurrence aft er a 12-year, single-center experience ofliver transplantations in patients with hepatocellular carcinoma. J Transplant 2010;
30. Kornberg A, Kupper B, Tannapfel A, et al. Long-term survivalaft er recurrent hepatocellular carcinoma in liver transplantpatients: clinical patterns and outcome variables. Eur J Surg Oncol 2010;36:275-280
31. Hollebecque A, Decaens T, Boleslawski E, et al. Natural history andtherapeutic management of recurrent hepatocellular carcinomaaft er liver transplantation. Gastroenterol Clin Biol 2009;33:361-369
32. Herrero JI, Sangro B, Quiroga J, et al. Infl uence of tumorcharacteristics on the outcome of liver transplantation amongpatients with liver cirrhosis and hepatocellular carcinoma. LiverTransplant 2001;7:631-636
33. Toso C, Merani S, Bigam DL, et al. Sirolimus-basedimmunosuppression is associated with increased survival aft erliver transplantation for hepatocellular carcinoma. Hepatology 2010;51:1237-1243
34. Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimusbasedimmunosuppression following liver transplantation forhepatocellular carcinoma. Liver Transplant 2008;14:633-638
35. Bjornsti MA, Houghton PJ. Th e TOR pathway: a target for cancertherapy. Nat Rev Cancer 2004;4:335-348
36. Price DJ, Grove JR, Calvo V, et al. Rapamycin-induced inhibition ofthe 70-kilodalton S6 protein kinase. Science 1992;257:973-977
37. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTORsignaling in hepatocellular carcinoma. Gastroenterology 2008 ;135:1972-1983
38. Panaro F, Piardi T, Gheza F, et al. Causes of sirolimusdiscontinuation in 97 liver transplant recipients. Transplant Proc 2011;43: 1128-1131
39. Vivarelli M, Dazzi A, Zanello M, et al. Eff ect of diff erentimmunosuppressive schedules on recurrence-free survival aft erliver transplantation for hepatocellular carcinoma. Transplantation 2010;89:227-231
40. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on therecurrence of hepatocellular carcinoma aft er liver transplantation. Liver Transplant 2009;15:1834-1842
41. Zimmerman MA, Trotter JF, Wachs M, et al. Predictors of longtermoutcome following liver transplantation for hepatocellularcarcinoma: a single-center experience. Transplant Int 2007;20:747-753
42. Zhou J, Wang Z, Wu ZQ, et al. Sirolimus-based immunosuppressiontherapy in liver transplantation for patients with hepatocellularcarcinoma exceeding the Milan criteria. Transplant Proc 2008;40:3548-3553
43. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrenceand survival following the use of sirolimus in liver transplantationfor hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37:411-419
44. Nocera A, Andorno E, Tagliamacco A, et al. Sirolimus therapy inliver transplant patients: an initial experience at a single center. Transplant Proc 2008;40: 1950-1952
45. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-basedimmunosuppression aft er liver transplantation for hepatocellularcarcinoma: long-term outcomes and side eff ects. Transplantation 2007;83:1162-1168
46. Cholongitas E, Mamou C, Rodriguez-Castro KI, et al. Mammaliantarget of rapamycin inhibitors are associated with lower rates ofhepatocellular carcinoma recurrence aft er liver transplantation: asystematic review. Transplant Int 2014;27:1039-1049
47. Saliba F, De Simone P, Nevens F, et al. Renal function at twoyears in liver transplant patients receiving everolimus: results ofa randomized, multicenter study. Am J Transplant 2013;13:1734-1745
48. Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospectiverandomised, open-labeled, trial comparing sirolimus-containingversus mTOR-inhibitor-free immunosuppression in patientsundergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010;10:190
49. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advancedhepatocellular carcinoma. N Engl J Med 2008;359:378-390
50. Bhoori S, Toff anin S, Sposito C, et al. Personalized moleculartargeted therapy in advanced, recurrent hepatocellular carcinomaaft er liver transplantation: a proof of principle. J Hepatol 2010;52:771-775
51. Kim R, El-Gazzaz G, Tan A, et al. Safety and feasibility of usingsorafenib in recurrent hepatocellular carcinoma aft er orthotopicliver transplantation. Oncology 2010;79:62-66
52. Waidmann O, Hofmann WP, Zeuzem S, et al. mTOR inhibitors andsorafenib for recurrent heptocellular carcinoma aft er orthotopicliver transplantation. J Hepatol 2011;54:396-398
53. Newell P, Toff anin S, Villanueva A, et al. Ras pathway activationin hepatocellular carcinoma and anti-tumoral eff ect of combinedsorafenib and rapamycin in vivo. J Hepatol 2009;51:725-733
54. Wang Z, Zhou J, Fan J, et al. Eff ect of rapamycin alone and incombination with sorafenib in an orthotopic model of humanhepatocellular carcinoma. Clin Cancer Res 2008;14:5124-5130
55. Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Effi cacyand safety of sorafenib in combination with mammalian target ofrapamycin inhibitors for recurrent hepatocellular carcinoma aft erliver transplantation. Liver Transplant 2012;18:45-52
56. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines toevaluate the response to treatment in solid tumors. EuropeanOrganization for Research and Treatment of Cancer, NationalCancer Institute of the United States, National Cancer Institute ofCanada. J Natl Cancer Inst 2000;92:205-216.